Glottic cancer: altered-fractionation radiotherapy enhances local control

  • Oral Oncol

  • curated by Brian Richardson, PhD
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Altered-fractionation radiotherapy (ART) is associated with fewer local failure events compared with chemoradiotherapy (CRT) in patients with early-stage (T1/T2) glottic carcinoma, according to a systematic review and meta-analysis.
  • Significant benefit in T1 tumors may not extend to T2 disease.

Why this matters

  • ART had previously shown relative benefits for a general population of patients with head and neck cancer; this study shows specific benefit for glottic cancer.

Key results

  • ART was associated with fewer local failure events compared with CRT in an analysis of randomized controlled trials (RCTs; HR, 0.62; P=.0009) and retrospective studies (HR, 0.40; P=.0003).
  • Hyperfractionation ART (HR, 0.65; P=.03) and hypofractionation ART (HR, 0.55; P=.02) were both associated with fewer local failure events compared with CRT.
  • The benefit of ART was significant in studies with >50% patients with T1 disease (HR, 0.49; P<.00001 but not in studies with>50% patients with T2 disease (HR, 0.60; P=.15).

Study design

  • 11 studies (4 RCTs and 7 two-group retrospective studies, 1762 total patients) were included in the meta-analysis.
  • Funding: None.

Limitations

  • Inclusion of retrospective studies.
  • Relatively small number of patients with T2 disease.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit